TuHURA Biosciences (HURA) announced that the U.S FDA Office of Orphan Products Development has granted Orphan Drug Designation to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA:
- TuHURA Biosciences Receives Nasdaq Minimum Bid Price Notice
- TuHURA Biosciences price target lowered to $10 from $12 at H.C. Wainwright
- TuHURA Biosciences announces release of Kintara’s CVR
- TuHURA Biosciences provides updates across portfolio
- TuHURA Biosciences Announces Securities Purchase Agreement